MicroRNAs targeting the SARS-CoV-2 entry receptor ACE2 in cardiomyocytes
The World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) as a public health emergency of international concern as more than 15 million cases were reported by 24th July 2020. Angiotensin-converting enzyme 2 (ACE2) is a COVID-19 entry receptor regulating host cell infection. A...
Saved in:
| Published in | Journal of molecular and cellular cardiology Vol. 148; pp. 46 - 49 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Elsevier Ltd
01.11.2020
The Authors. Published by Elsevier Ltd |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) as a public health emergency of international concern as more than 15 million cases were reported by 24th July 2020. Angiotensin-converting enzyme 2 (ACE2) is a COVID-19 entry receptor regulating host cell infection. A recent study reported that ACE2 is expressed in cardiomyocytes. In this study, we aimed to explore if there are microRNA (miRNA) molecules which target ACE2 and which may be exploited to regulate the SARS-CoV-2 receptor. Our data reveal that both Ace2 mRNA and Ace2 protein levels are inhibited by miR-200c in rat primary cardiomyocytes and importantly, in human iPSC-derived cardiomyocytes. We report the first miRNA candidate that can target ACE2 in cardiomyocytes and thus may be exploited as a preventive strategy to treat cardiovascular complications of COVID-19.
•ACE2 is expressed in various cardiovascular cells including cardiomyocytes.•MicroRNA molecules can play an important role in ACE2 regulation.•MiR-200c can modulate ACE2 expression in both rat and human cardiomyocytes. |
|---|---|
| AbstractList | The World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) as a public health emergency of international concern as more than 15 million cases were reported by 24th July 2020. Angiotensin-converting enzyme 2 (ACE2) is a COVID-19 entry receptor regulating host cell infection. A recent study reported that ACE2 is expressed in cardiomyocytes. In this study, we aimed to explore if there are microRNA (miRNA) molecules which target ACE2 and which may be exploited to regulate the SARS-CoV-2 receptor. Our data reveal that both Ace2 mRNA and Ace2 protein levels are inhibited by miR-200c in rat primary cardiomyocytes and importantly, in human iPSC-derived cardiomyocytes. We report the first miRNA candidate that can target ACE2 in cardiomyocytes and thus may be exploited as a preventive strategy to treat cardiovascular complications of COVID-19.The World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) as a public health emergency of international concern as more than 15 million cases were reported by 24th July 2020. Angiotensin-converting enzyme 2 (ACE2) is a COVID-19 entry receptor regulating host cell infection. A recent study reported that ACE2 is expressed in cardiomyocytes. In this study, we aimed to explore if there are microRNA (miRNA) molecules which target ACE2 and which may be exploited to regulate the SARS-CoV-2 receptor. Our data reveal that both Ace2 mRNA and Ace2 protein levels are inhibited by miR-200c in rat primary cardiomyocytes and importantly, in human iPSC-derived cardiomyocytes. We report the first miRNA candidate that can target ACE2 in cardiomyocytes and thus may be exploited as a preventive strategy to treat cardiovascular complications of COVID-19. The World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) as a public health emergency of international concern as more than 15 million cases were reported by 24th July 2020. Angiotensin-converting enzyme 2 (ACE2) is a COVID-19 entry receptor regulating host cell infection. A recent study reported that ACE2 is expressed in cardiomyocytes. In this study, we aimed to explore if there are microRNA (miRNA) molecules which target ACE2 and which may be exploited to regulate the SARS-CoV-2 receptor. Our data reveal that both Ace2 mRNA and Ace2 protein levels are inhibited by miR-200c in rat primary cardiomyocytes and importantly, in human iPSC-derived cardiomyocytes. We report the first miRNA candidate that can target ACE2 in cardiomyocytes and thus may be exploited as a preventive strategy to treat cardiovascular complications of COVID-19. •ACE2 is expressed in various cardiovascular cells including cardiomyocytes.•MicroRNA molecules can play an important role in ACE2 regulation.•MiR-200c can modulate ACE2 expression in both rat and human cardiomyocytes. The World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) as a public health emergency of international concern as more than 15 million cases were reported by 24th July 2020. Angiotensin-converting enzyme 2 (ACE2) is a COVID-19 entry receptor regulating host cell infection. A recent study reported that ACE2 is expressed in cardiomyocytes. In this study, we aimed to explore if there are microRNA (miRNA) molecules which target ACE2 and which may be exploited to regulate the SARS-CoV-2 receptor. Our data reveal that both Ace2 mRNA and Ace2 protein levels are inhibited by miR-200c in rat primary cardiomyocytes and importantly, in human iPSC-derived cardiomyocytes. We report the first miRNA candidate that can target ACE2 in cardiomyocytes and thus may be exploited as a preventive strategy to treat cardiovascular complications of COVID-19. • ACE2 is expressed in various cardiovascular cells including cardiomyocytes. • MicroRNA molecules can play an important role in ACE2 regulation. • MiR-200c can modulate ACE2 expression in both rat and human cardiomyocytes. The World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) as a public health emergency of international concern as more than 15 million cases were reported by 24th July 2020. Angiotensin-converting enzyme 2 (ACE2) is a COVID-19 entry receptor regulating host cell infection. A recent study reported that ACE2 is expressed in cardiomyocytes. In this study, we aimed to explore if there are microRNA (miRNA) molecules which target ACE2 and which may be exploited to regulate the SARS-CoV-2 receptor. Our data reveal that both Ace2 mRNA and Ace2 protein levels are inhibited by miR-200c in rat primary cardiomyocytes and importantly, in human iPSC-derived cardiomyocytes. We report the first miRNA candidate that can target ACE2 in cardiomyocytes and thus may be exploited as a preventive strategy to treat cardiovascular complications of COVID-19. |
| Author | Xiao, Ke Wang, Yibin Thum, Thomas Foo, Roger Lu, Dongchao Bär, Christian Chatterjee, Shambhabi Riedel, Isabelle |
| Author_xml | – sequence: 1 givenname: Dongchao surname: Lu fullname: Lu, Dongchao organization: Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany – sequence: 2 givenname: Shambhabi surname: Chatterjee fullname: Chatterjee, Shambhabi organization: Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany – sequence: 3 givenname: Ke surname: Xiao fullname: Xiao, Ke organization: Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany – sequence: 4 givenname: Isabelle surname: Riedel fullname: Riedel, Isabelle organization: Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany – sequence: 5 givenname: Yibin surname: Wang fullname: Wang, Yibin organization: Department of Anesthesiology, Medicine and Physiology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA – sequence: 6 givenname: Roger surname: Foo fullname: Foo, Roger organization: Genome Institute of Singapore, Cardiovascular Research Institute, National University of Singapore, Centre for Translational Medicine, Singapore, Republic of Singapore – sequence: 7 givenname: Christian surname: Bär fullname: Bär, Christian email: baer.christian@mh-hannover.de organization: Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany – sequence: 8 givenname: Thomas surname: Thum fullname: Thum, Thomas email: thum.thomas@mh-hannover.de organization: Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32891636$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkVFv0zAUhS00xLrCL0BCeeQl4dpx4lgIpKoaG9IAaQNeLde-6VySuLPdSfn3pOuGYA9MsuSHe75z7XNOyNHgByTkNYWCAq3fbYpx0xtTMGBQQFMAFc_IjIKs8qZq-BGZATCWs4Y1x-Qkxg0ASF6WL8hxyRpJ67KekfMvzgR_-XURs6TDGpMb1lm6xuxqcXmVL_3PnGU4pDBmAQ1ukw_ZYnnKMjdkRgfrfD96MyaML8nzVncRX93fc_Lj0-n35Xl-8e3s83JxkZtKiJSXAk0lrZGt0MbaigOz0zEryStYyYpR0C3auuQrrUHSlktRTWMt21Jobss5-Xjw3e5WPVqzf5zu1Da4XodRee3Uv5PBXau1v1WCCxDT_-fk7b1B8Dc7jEn1LhrsOj2g30XFOIe6Fqymk_TN37v-LHmIbxLIg2DKMMaArTIu6eT8frXrFAW1r0pt1F1Val-VgkZNVU1s-Yh9sP8_9eFA4ZTxrcOgonE4GLRuKigp690T_PtHvOnc4IzufuH4JP0bwvjCvg |
| CitedBy_id | crossref_primary_10_1007_s00705_021_05152_5 crossref_primary_10_1007_s10863_023_10000_z crossref_primary_10_1186_s12931_023_02413_6 crossref_primary_10_17816_RCF192145_174 crossref_primary_10_35366_103452 crossref_primary_10_1038_s41392_022_00907_1 crossref_primary_10_1371_journal_ppat_1009950 crossref_primary_10_3389_fcell_2023_1229393 crossref_primary_10_1016_j_yjmcc_2021_11_003 crossref_primary_10_1097_FJC_0000000000001201 crossref_primary_10_3389_fmed_2023_1187557 crossref_primary_10_20463_pan_2021_0008 crossref_primary_10_3892_ijmm_2021_5075 crossref_primary_10_1126_scitranslmed_abm9151 crossref_primary_10_3389_fmed_2024_1430974 crossref_primary_10_1002_ejhf_2322 crossref_primary_10_1080_15384101_2020_1867792 crossref_primary_10_1021_acs_jproteome_0c00372 crossref_primary_10_1124_jpet_122_001210 crossref_primary_10_3390_ijms222011279 crossref_primary_10_1007_s10439_022_03094_w crossref_primary_10_2174_26669587_v2_e221026_2022_23 crossref_primary_10_3390_ijms23158285 crossref_primary_10_3390_v15081647 crossref_primary_10_1016_j_heliyon_2024_e40297 crossref_primary_10_1186_s12865_024_00675_3 crossref_primary_10_1080_15476286_2021_2010959 crossref_primary_10_3390_life12020288 crossref_primary_10_1007_s11010_022_04356_w crossref_primary_10_3390_ncrna8030029 crossref_primary_10_14336_AD_2023_0314 crossref_primary_10_1016_j_meegid_2022_105207 crossref_primary_10_1016_j_jpha_2021_03_003 crossref_primary_10_1038_s41573_021_00219_z crossref_primary_10_1016_j_intimp_2020_107204 crossref_primary_10_2147_DDDT_S450499 crossref_primary_10_2174_1381612827666210114150951 crossref_primary_10_1002_ejhf_2631 crossref_primary_10_3390_ijms232012292 crossref_primary_10_1016_j_virusres_2022_198853 crossref_primary_10_1002_wsbm_1621 crossref_primary_10_1016_j_intimp_2021_108232 crossref_primary_10_1016_j_virusres_2021_198631 crossref_primary_10_3390_cells11081316 crossref_primary_10_1002_cbf_3648 crossref_primary_10_1016_j_genrep_2022_101641 crossref_primary_10_3390_ijms22168663 crossref_primary_10_1016_j_semcancer_2021_01_003 crossref_primary_10_1016_j_biopha_2024_116984 crossref_primary_10_1016_j_jviromet_2021_114424 crossref_primary_10_1111_liv_16079 crossref_primary_10_3390_cells12192421 crossref_primary_10_3390_jpm12030386 crossref_primary_10_1038_s41366_021_00984_2 crossref_primary_10_3390_v14010041 crossref_primary_10_3389_fimmu_2021_763313 crossref_primary_10_1042_CS20220235 crossref_primary_10_1007_s10096_021_04264_9 crossref_primary_10_3390_cells11152279 crossref_primary_10_3390_biomedicines9091142 crossref_primary_10_3389_fgene_2022_891159 crossref_primary_10_3390_diagnostics13061091 crossref_primary_10_3390_genes13020348 crossref_primary_10_3389_fcimb_2022_998748 crossref_primary_10_1186_s12985_023_02152_6 crossref_primary_10_3390_cells9112508 crossref_primary_10_1002_med_22073 crossref_primary_10_1002_jccs_202200140 crossref_primary_10_1007_s12268_021_1620_6 crossref_primary_10_33393_jcb_2022_2356 crossref_primary_10_2217_epi_2023_0179 crossref_primary_10_1016_j_jare_2020_11_013 crossref_primary_10_1093_bib_bbab062 crossref_primary_10_1016_j_meegid_2021_104832 crossref_primary_10_1016_j_jmccpl_2022_100013 crossref_primary_10_1002_ejhf_2096 crossref_primary_10_15275_rusomj_2022_0313 crossref_primary_10_3238_PersKardio_2021_10_15_06 crossref_primary_10_1002_btm2_10581 crossref_primary_10_1016_j_ncrna_2024_08_007 crossref_primary_10_3390_ijms22105263 crossref_primary_10_2174_1389200223666220321102824 crossref_primary_10_3390_ijms222212243 crossref_primary_10_3390_vaccines11121814 crossref_primary_10_1016_j_jiph_2022_06_012 crossref_primary_10_1016_j_gene_2023_147232 crossref_primary_10_1186_s12967_020_02582_8 crossref_primary_10_3389_fcimb_2024_1407261 |
| Cites_doi | 10.1016/j.cell.2020.02.052 10.1155/2015/896861 10.1056/NEJMc2011400 10.1093/eurheartj/ehaa311 10.1111/jvim.15454 10.1016/j.yjmcc.2020.04.031 10.1002/ejhf.1828 10.1016/j.biopha.2020.110037 10.1056/NEJMoa2002032 10.1042/CS20171121 10.1016/j.scr.2017.03.022 10.1038/d41573-020-00073-5 10.46234/ccdcw2020.032 10.1093/cvr/cvaa160 10.1161/JAHA.120.016219 |
| ContentType | Journal Article |
| Copyright | 2020 The Authors Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved. 2020 The Authors 2020 |
| Copyright_xml | – notice: 2020 The Authors – notice: Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved. – notice: 2020 The Authors 2020 |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1016/j.yjmcc.2020.08.017 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1095-8584 |
| EndPage | 49 |
| ExternalDocumentID | PMC7470794 32891636 10_1016_j_yjmcc_2020_08_017 S0022282820302741 |
| Genre | Journal Article |
| GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29L 3O- 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABGSF ABJNI ABLJU ABMAC ABMZM ABUDA ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFGL ADMUD ADNMO ADUVX AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGRDE AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CAG COF CS3 DM4 DU5 EBS EFBJH EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEB HLW HMK HMO HVGLF HZ~ IHE J1W K-O KOM L7B LX2 M29 M41 MO0 N9A O-L O9- OAUVE OA~ OL0 OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SBG SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSZ T5K WUQ X7M XPP Z5R ZGI ZMT ZU3 ~G- 6I. AACTN AAFTH AAIAV ABLVK ABYKQ AEHWI AFKWA AHPSJ AJBFU AJOXV AMFUW DOVZS EFLBG LCYCR RIG SSU AAYXX AFCTW AGRNS CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c577t-37ec59dc9f7acdd5402d02dcb9450b95210afed634baa091f4975dcba9f37a4d3 |
| IEDL.DBID | .~1 |
| ISSN | 0022-2828 1095-8584 |
| IngestDate | Thu Aug 21 18:34:24 EDT 2025 Mon Jul 21 11:44:03 EDT 2025 Mon Jul 21 05:38:48 EDT 2025 Thu Apr 24 23:07:05 EDT 2025 Tue Jul 01 04:05:31 EDT 2025 Fri Feb 23 02:47:20 EST 2024 Tue Aug 26 17:12:01 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | COVID-19 ACE2 Cardiomyocytes miRNAs |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c577t-37ec59dc9f7acdd5402d02dcb9450b95210afed634baa091f4975dcba9f37a4d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally to this work. |
| OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0022282820302741 |
| PMID | 32891636 |
| PQID | 2440667261 |
| PQPubID | 23479 |
| PageCount | 4 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7470794 proquest_miscellaneous_2440667261 pubmed_primary_32891636 crossref_citationtrail_10_1016_j_yjmcc_2020_08_017 crossref_primary_10_1016_j_yjmcc_2020_08_017 elsevier_sciencedirect_doi_10_1016_j_yjmcc_2020_08_017 elsevier_clinicalkey_doi_10_1016_j_yjmcc_2020_08_017 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-11-01 |
| PublicationDateYYYYMMDD | 2020-11-01 |
| PublicationDate_xml | – month: 11 year: 2020 text: 2020-11-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Journal of molecular and cellular cardiology |
| PublicationTitleAlternate | J Mol Cell Cardiol |
| PublicationYear | 2020 |
| Publisher | Elsevier Ltd The Authors. Published by Elsevier Ltd |
| Publisher_xml | – name: Elsevier Ltd – name: The Authors. Published by Elsevier Ltd |
| References | Nicin, Abplanalp, Mellentin, Kattih, Tombor, John (bb0030) 2020; 41 Tavazzi, Pellegrini, Maurelli, Belliato, Sciutti, Bottazzi (bb0050) 2020; 22 Team TNCPERE (bb0025) 2020; 2 Gross, Jahn, Cushman, Bar, Thum (bb0040) 2020; 144 Chen, Xu, Yu, Chang, Zhong (bb0035) 2015; 2015 Thanh Le, Andreadakis, Kumar, Gomez Roman, Tollefsen, Saville (bb0070) 2020; 19 Puelles, Lutgehetmann, Lindenmeyer, Sperhake, Wong, Allweiss (bb0055) 2020; 383 D’Agostino, Martino, Sileno, Barilla, Beji, Marchetti (bb0080) 2017; 131 Bojkova, Wagner, Shumliakivska, Aslan, Saleem, Hansen (bb0065) 2020 Coronavirus disease (COVID-19) (bb0005) 2020 Guan, Ni, Hu, Liang, Ou, He (bb0010) 2020; 382 Guo, Huang, Lin, Lv (bb0085) 2020; 9 Wenzel, Kopp, Gobel, Jansen, Geyer, Hahn (bb0060) 2020; 116 Sharma, Garcia, Arumugaswami, Svendsen (bb0045) 2020 Kozak, Jonak, Maciejewski (bb0075) 2020; 125 Hoffmann, Kleine-Weber, Schroeder, Kruger, Herrler, Erichsen (bb0020) 2020; 181 Haase, Gohring, Martin (bb0090) 2017; 21 Ames, Atkins, Pitt (bb0015) 2019; 33 Chen (10.1016/j.yjmcc.2020.08.017_bb0035) 2015; 2015 Ames (10.1016/j.yjmcc.2020.08.017_bb0015) 2019; 33 Kozak (10.1016/j.yjmcc.2020.08.017_bb0075) 2020; 125 Sharma (10.1016/j.yjmcc.2020.08.017_bb0045) 2020 Puelles (10.1016/j.yjmcc.2020.08.017_bb0055) 2020; 383 Bojkova (10.1016/j.yjmcc.2020.08.017_bb0065) 2020 Coronavirus disease (COVID-19) (10.1016/j.yjmcc.2020.08.017_bb0005) 2020 Hoffmann (10.1016/j.yjmcc.2020.08.017_bb0020) 2020; 181 Thanh Le (10.1016/j.yjmcc.2020.08.017_bb0070) 2020; 19 Tavazzi (10.1016/j.yjmcc.2020.08.017_bb0050) 2020; 22 Guan (10.1016/j.yjmcc.2020.08.017_bb0010) 2020; 382 Wenzel (10.1016/j.yjmcc.2020.08.017_bb0060) 2020; 116 Haase (10.1016/j.yjmcc.2020.08.017_bb0090) 2017; 21 Gross (10.1016/j.yjmcc.2020.08.017_bb0040) 2020; 144 Nicin (10.1016/j.yjmcc.2020.08.017_bb0030) 2020; 41 D’Agostino (10.1016/j.yjmcc.2020.08.017_bb0080) 2017; 131 Guo (10.1016/j.yjmcc.2020.08.017_bb0085) 2020; 9 Team TNCPERE (10.1016/j.yjmcc.2020.08.017_bb0025) 2020; 2 |
| References_xml | – volume: 2 start-page: 113 year: 2020 end-page: 122 ident: bb0025 article-title: The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) — China publication-title: China CDC Wkly – year: 2020 ident: bb0045 article-title: Human iPSC-derived cardiomyocytes are susceptible to SARS-CoV-2 infection publication-title: bioRxiv – volume: 19 start-page: 305 year: 2020 end-page: 306 ident: bb0070 article-title: The COVID-19 vaccine development landscape publication-title: Nat. Rev. Drug Discov. – volume: 41 start-page: 1804 year: 2020 end-page: 1806 ident: bb0030 article-title: Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts publication-title: Eur. Heart J. – volume: 2015 year: 2015 ident: bb0035 article-title: The ACE2/Apelin signaling, MicroRNAs, and hypertension publication-title: Int. J. Hypertens. – volume: 22 start-page: 911 year: 2020 end-page: 915 ident: bb0050 article-title: Myocardial localization of coronavirus in COVID-19 cardiogenic shock publication-title: Eur. J. Heart Fail. – volume: 21 start-page: 71 year: 2017 end-page: 73 ident: bb0090 article-title: Generation of non-transgenic iPS cells from human cord blood CD34(+) cells under animal component-free conditions publication-title: Stem Cell Res. – volume: 116 start-page: 1661 year: 2020 end-page: 1663 ident: bb0060 article-title: Evidence of SARS-CoV-2 mRNA in endomyocardial biopsies of patients with clinically suspected myocarditis tested negative for COVID-19 in nasopharyngeal swab publication-title: Cardiovasc. Res. – volume: 383 start-page: 590 year: 2020 end-page: 592 ident: bb0055 article-title: Multiorgan and renal tropism of SARS-CoV-2 publication-title: N. Engl. J. Med. – volume: 125 year: 2020 ident: bb0075 article-title: The function of miR-200 family in oxidative stress response evoked in cancer chemotherapy and radiotherapy publication-title: Biomed. Pharmacother. – volume: 382 start-page: 1708 year: 2020 end-page: 1720 ident: bb0010 article-title: Clinical characteristics of coronavirus disease 2019 in China publication-title: N. Engl. J. Med. – year: 2020 ident: bb0005 article-title: Situation Report – 186 – volume: 33 start-page: 363 year: 2019 end-page: 382 ident: bb0015 article-title: The renin-angiotensin-aldosterone system and its suppression publication-title: J. Vet. Intern. Med. – year: 2020 ident: bb0065 article-title: SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes publication-title: bioRxiv – volume: 131 start-page: 2397 year: 2017 end-page: 2408 ident: bb0080 article-title: Circulating miR-200c is up-regulated in paediatric patients with familial hypercholesterolaemia and correlates with miR-33a/b levels: implication of a ZEB1-dependent mechanism publication-title: Clin. Sci. – volume: 144 start-page: 47 year: 2020 end-page: 53 ident: bb0040 article-title: SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: from basic science to clinical implications publication-title: J. Mol. Cell. Cardiol. – volume: 181 start-page: 271 year: 2020 end-page: 80 e8 ident: bb0020 article-title: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor publication-title: Cell – volume: 9 year: 2020 ident: bb0085 article-title: Coronavirus disease 2019 (COVID-19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection publication-title: J. Am. Heart Assoc. – volume: 181 start-page: 271 year: 2020 ident: 10.1016/j.yjmcc.2020.08.017_bb0020 article-title: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor publication-title: Cell doi: 10.1016/j.cell.2020.02.052 – volume: 2015 year: 2015 ident: 10.1016/j.yjmcc.2020.08.017_bb0035 article-title: The ACE2/Apelin signaling, MicroRNAs, and hypertension publication-title: Int. J. Hypertens. doi: 10.1155/2015/896861 – volume: 383 start-page: 590 year: 2020 ident: 10.1016/j.yjmcc.2020.08.017_bb0055 article-title: Multiorgan and renal tropism of SARS-CoV-2 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMc2011400 – volume: 41 start-page: 1804 year: 2020 ident: 10.1016/j.yjmcc.2020.08.017_bb0030 article-title: Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts publication-title: Eur. Heart J. doi: 10.1093/eurheartj/ehaa311 – volume: 33 start-page: 363 year: 2019 ident: 10.1016/j.yjmcc.2020.08.017_bb0015 article-title: The renin-angiotensin-aldosterone system and its suppression publication-title: J. Vet. Intern. Med. doi: 10.1111/jvim.15454 – year: 2020 ident: 10.1016/j.yjmcc.2020.08.017_bb0065 article-title: SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes publication-title: bioRxiv – volume: 144 start-page: 47 year: 2020 ident: 10.1016/j.yjmcc.2020.08.017_bb0040 article-title: SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: from basic science to clinical implications publication-title: J. Mol. Cell. Cardiol. doi: 10.1016/j.yjmcc.2020.04.031 – volume: 22 start-page: 911 year: 2020 ident: 10.1016/j.yjmcc.2020.08.017_bb0050 article-title: Myocardial localization of coronavirus in COVID-19 cardiogenic shock publication-title: Eur. J. Heart Fail. doi: 10.1002/ejhf.1828 – volume: 125 year: 2020 ident: 10.1016/j.yjmcc.2020.08.017_bb0075 article-title: The function of miR-200 family in oxidative stress response evoked in cancer chemotherapy and radiotherapy publication-title: Biomed. Pharmacother. doi: 10.1016/j.biopha.2020.110037 – volume: 382 start-page: 1708 year: 2020 ident: 10.1016/j.yjmcc.2020.08.017_bb0010 article-title: Clinical characteristics of coronavirus disease 2019 in China publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2002032 – volume: 131 start-page: 2397 year: 2017 ident: 10.1016/j.yjmcc.2020.08.017_bb0080 article-title: Circulating miR-200c is up-regulated in paediatric patients with familial hypercholesterolaemia and correlates with miR-33a/b levels: implication of a ZEB1-dependent mechanism publication-title: Clin. Sci. doi: 10.1042/CS20171121 – volume: 21 start-page: 71 year: 2017 ident: 10.1016/j.yjmcc.2020.08.017_bb0090 article-title: Generation of non-transgenic iPS cells from human cord blood CD34(+) cells under animal component-free conditions publication-title: Stem Cell Res. doi: 10.1016/j.scr.2017.03.022 – volume: 19 start-page: 305 year: 2020 ident: 10.1016/j.yjmcc.2020.08.017_bb0070 article-title: The COVID-19 vaccine development landscape publication-title: Nat. Rev. Drug Discov. doi: 10.1038/d41573-020-00073-5 – volume: 2 start-page: 113 year: 2020 ident: 10.1016/j.yjmcc.2020.08.017_bb0025 article-title: The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) — China publication-title: China CDC Wkly doi: 10.46234/ccdcw2020.032 – year: 2020 ident: 10.1016/j.yjmcc.2020.08.017_bb0045 article-title: Human iPSC-derived cardiomyocytes are susceptible to SARS-CoV-2 infection publication-title: bioRxiv – year: 2020 ident: 10.1016/j.yjmcc.2020.08.017_bb0005 – volume: 116 start-page: 1661 year: 2020 ident: 10.1016/j.yjmcc.2020.08.017_bb0060 article-title: Evidence of SARS-CoV-2 mRNA in endomyocardial biopsies of patients with clinically suspected myocarditis tested negative for COVID-19 in nasopharyngeal swab publication-title: Cardiovasc. Res. doi: 10.1093/cvr/cvaa160 – volume: 9 year: 2020 ident: 10.1016/j.yjmcc.2020.08.017_bb0085 publication-title: J. Am. Heart Assoc. doi: 10.1161/JAHA.120.016219 |
| SSID | ssj0009433 |
| Score | 2.5886233 |
| Snippet | The World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) as a public health emergency of international concern as more than 15 million... |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 46 |
| SubjectTerms | ACE2 Angiotensin-Converting Enzyme 2 - genetics Animals Cardiomyocytes Cells, Cultured Computer Simulation COVID-19 COVID-19 - genetics COVID-19 - virology Fibroblasts - metabolism Human Umbilical Vein Endothelial Cells Humans Induced Pluripotent Stem Cells - cytology Mice MicroRNAs - genetics miRNAs Myocardium - metabolism Myocytes, Cardiac - metabolism Myocytes, Cardiac - virology Rats Real-Time Polymerase Chain Reaction SARS-CoV-2 Short Communication |
| Title | MicroRNAs targeting the SARS-CoV-2 entry receptor ACE2 in cardiomyocytes |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0022282820302741 https://dx.doi.org/10.1016/j.yjmcc.2020.08.017 https://www.ncbi.nlm.nih.gov/pubmed/32891636 https://www.proquest.com/docview/2440667261 https://pubmed.ncbi.nlm.nih.gov/PMC7470794 |
| Volume | 148 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fT9swED4hkCZepv0A1jGQJ-1xgTSxY_wYVUXdKvpQxuDNsh1HFI20Gu1DX_jbuXOSQtnEpCmWosS2lJzt83fJd3cAX3jqutIVZVQUIo64SXxklEgjIzKZlapEyBsIsqNscMG_X4mrDei1vjBEq2x0f63Tg7Zu7hw30jyeTSbk40tfL_CI0xCEhTzYuaRZfnT_SPNQvE4nT6x1at1GHgocr-XNraM4hkkc4niGrGV_3Z3-RJ_PSZRPdqXTN_C6gZMsr5_4LWz46h28Omt-mL-HwRkR7saj_I7VnG_cqRhiPnaej8-j3vRnlLCQW4ShFPwMDXCW9_oJm1TMBabq7XLqlghHd-DitP-jN4ia5AmRE1LOUXF4J1ThVCmNw4FAO7HA4qziIrYKd-3YlL7IUm6NQdBQciUFVhtVptLwIt2FzWpa-Q_AskJ0fewcd7h4vRUWi7TxiS9lZhPb7UDSCk27JrI4Jbj4pVsK2Y0OktYkaU1pL7uyA19XnWZ1YI2Xm_N2NHTrM4paTqPif7lbtuq2Nq3-3fFzO-QaFxz9RTGVny7uNOIhIgaj5dmBvXoKrF4gRfMVAW7WAbk2OVYNKJj3ek01uQ5BvdGsi1G8H__3gfdhm65qN8lPsDn_vfAHiJfm9jAsiEPYyr8NByM6D8eXwwcj6xcb |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1BT9swFH7qQNp2mQZsrIMxI3EkI03sGB-riqqwtgegqDfLdhxRRNOKlkMv_HaenaSsGyrSFJ9iW3Ke7efvxd97D-CIxqbBTZoFacrCgKrIBkqwOFAs4UkmMoS8niDbTzoDejFkwxq0Kl8YR6ssdX-h0722Lt-clNI8mY5GzsfX_b3AJ4x9EJZ3sElx-7o0Br-eXngeghb55B1t3TWvQg95ktfibmxcIMMo9IE8fdqyV4-nf-Hn3yzKP46l9mf4VOJJ0iyGvAU1m2_D-155Y74DnZ5j3F32mzNSkL7xqCII-shV8_IqaE1ugoj45CIExWCnaIGTZussIqOcGE9VHS8mZoF49AsM2mfXrU5QZk8IDON8jprDGiZSIzKuDM4EGoopFqMFZaEWeGyHKrNpElOtFKKGjArOsFqJLOaKpvFX2Mgnuf0GJElZw4bGUIO712qmsXAdntqMJzrSjTpEldCkKUOLuwwX97LikN1JL2npJC1d3ssGr8PxstO0iKyxvjmtZkNWTqOo5iRq_vXdkmW3lXX1dsfDasol7jh3jaJyO3mcSQREjhmMpmcddoslsPyAGO1XRLhJHfjK4lg2cNG8V2vy0a2P6o12XYji_f6_A_4JHzrXva7snvd_78FHV1P4TO7Dxvzh0f5A8DTXB35zPAOfaBcG |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=MicroRNAs+targeting+the+SARS-CoV-2+entry+receptor+ACE2+in+cardiomyocytes&rft.jtitle=Journal+of+molecular+and+cellular+cardiology&rft.au=Lu%2C+Dongchao&rft.au=Chatterjee%2C+Shambhabi&rft.au=Xiao%2C+Ke&rft.au=Riedel%2C+Isabelle&rft.date=2020-11-01&rft.pub=The+Authors.+Published+by+Elsevier+Ltd&rft.issn=0022-2828&rft.eissn=1095-8584&rft.volume=148&rft.spage=46&rft.epage=49&rft_id=info:doi/10.1016%2Fj.yjmcc.2020.08.017&rft_id=info%3Apmid%2F32891636&rft.externalDocID=PMC7470794 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-2828&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-2828&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-2828&client=summon |